Market Herald logo


Be the first with the news that moves the market
  • iCo Therapeutics (ICO) has completed the Phase 1b dosing for the company’s oral Amphotericin B study. 
  • Results from Phase 1b should be available before the end of 2020’s first quarter.
  • Phase 1b results will be used to improve Phase 2 of the clinical study on vulvovaginal candidiasis (VVC). 
  • iCo’s share price is down 7.14 per cent, with shares trading at $0.06 apiece.

Biotechnology company iCo Therapeutics (ICO), and its Australian subsidiary, have completed Phase 1b dosing for the oral Amphotericin B study.

The ongoing study will test how well the oral form of antifungal drug Amphotericin B can treat vulvovaginal candidiasis (VVC), a yeast infection.  

All subjects in Phase 1b of the study have received varying doses of oral Amphotericin B over 10 days. Subsequent to dosing, subjects have been followed up for an additional 10 days.

The results of the Phase 1b dosing should be available before the end of 2020’s first quarter. iCo’s Chief Medical Officer, Dr Peter Hnik, spoke about how the results will benefit the overall study.

“Results from the Phase 1b study using multiple ascending doses of oral Amphotericin B will provide additional safety and pharmacokinetic information needed for the upcoming Phase 2 clinical study in patients with vulvovaginal candidiasis.”

The Phase 2 study will compare oral Amphotericin B to Fluconazole, another antifungal medication, in a head-to-head study. The Phase 2 study is scheduled to start in 2020’s second quarter.

According to Denning et al, “Worldwide, recurrent vulvovaginal candidiasis affects about 138 million [people] annually, with a global annual prevalence of 3,871 per 100 000 [people]. 372 million [people] are affected by recurrent vulvovaginal candidiasis over their lifetime.”

“By 2030, the population of [people] with recurrent vulvovaginal candidiasis each year is estimated to increase to almost 158 million, resulting in 20,240,664 extra cases […]. In high-income countries, the economic burden from lost productivity could be up to $14.39 billion USD.

iCo’s share price is down 7.14 per cent, with shares trading at $0.06 apiece.

More From The Market Herald
Neuralink - Founder, Elon Musk.

" Neuralink brain chips approved for human trials

Elon Musk’s Neuralink, a brain implant firm, has received regulatory approval for U.S. human trials.

" BioSyent reports Q1 2023 financial results

BioSyent (TSXV:RX) released its financial results for the three months ended March 31, 2023.

" Highmark Interactive approved for reimbursement services of remote patient monitoring devices

Highmark Interactive (V.HMRK) has been processed for remote patient monitoring and reimbursed by Medicare for those services.

" New data to be highlighted at the world’s top cancer conference

Next week, top health care firms will converge or the biggest cancer conference in the world.